Eli Lilly (LLY) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$79.7B

Revenue (quarter)

$23.0B

Revenue growth (year over year)

+47.67%

Gross profit (trailing twelve months)

$66.4B

Gross margin

83.40%

Net income (trailing twelve months)

$26.7B

Net income (quarter)

$7.1B

Net income growth (year over year)

+25.33%

Net margin

33.53%

Return on equity

102.44%

EPS (trailing twelve months)

$29.85

Book value per share

$35.98

P/E (trailing twelve months)

41.18

Price to book

32.47

Debt to assets

76.19%

Payout ratio

27.53%

Dividend yield

0.57%

Company profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

• Is Eli Lilly (LLY) profitable?

  Yes. Eli Lilly earned $26.7B in net income over the trailing twelve months, a net margin of 33.53%.

• How much revenue does Eli Lilly (LLY) make?

  Eli Lilly generated $79.7B in revenue over the trailing twelve months, up 47.67% year over year.

• What is LLY's P/E ratio?

  Eli Lilly trades at 41.2 times trailing twelve-month earnings, on an EPS of $29.85.

• How do I buy stock in Eli Lilly (LLY)?

  LLY trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.